Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoplasmacytic Lymphoma: early-phase trial registry
10 of 19 indexed Lymphoplasmacytic Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 10 currently recruiting · #902 of 28,707 conditions by registered trial count
Lymphoplasmacytic Lymphoma: 19 US clinical trials tracked, 10 recruiting.
Lymphoplasmacytic Lymphoma is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is C. Babis Andreadis, running 1 of these trials.
Enrollment posture brief
Registry condition lymphoplasmacytic-lymphoma
OPEN 10 | RECR 53% | LATE 0 | EARLY 17 | RANK #902 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Colorectal Cancer Metastatic (53% recruiting · 19 trials)
Lymphoplasmacytic Lymphoma lists 10 open slots (53% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoplasmacytic Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoplasmacytic Lymphoma is recruiting above its size-band peers.
10 of 19 indexed trials (52.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoplasmacytic Lymphoma trials is spread across many organizations.
C. Babis Andreadis accounts for 1 of 19 trials (5.3%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Lymphoplasmacytic Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 19 trials that report a genuine target (sentinel values excluded). 15 of those (78.9%) plan for fewer than 100 participants.
-
Lymphoplasmacytic Lymphoma research is mostly interventional.
18 interventional and 1 observational studies make up this index (94.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
National Heart, Lung, and Blood Institute (NHLBI)
NCT00923507
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
NCT06340737
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
NCT04840602
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
NCT04883437
64Cu-LLP2A for Imaging Hematologic Malignancies
Washington University School of Medicine
NCT06636175
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Memorial Sloan Kettering Cancer Center
NCT07231952
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
UNC Lineberger Comprehensive Cancer Center
NCT06860880
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
NCT04545762
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Shayna Sarosiek, MD
NCT06986174
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister
NCT05281809
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Cellectar Biosciences
NCT02952508
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
NCT02339922
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT03884998
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma
M.D. Anderson Cancer Center
NCT01209871
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Gilead Sciences
NCT01282424
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT00644189
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Masonic Cancer Center, University of Minnesota
NCT03019666
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
NCT00142129
Imexon for Relapsed Follicular and Aggressive Lymphomas
University of Rochester
NCT01314014
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoplasmacytic Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoplasmacytic Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoplasmacytic Lymphoma page
19 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Lymphoplasmacytic Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- C. Babis Andreadis sponsors the most Lymphoplasmacytic Lymphoma trials on record, review their full trial history before evaluating a specific study. See C. Babis Andreadis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoplasmacytic Lymphoma condition card totals 19 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.